July 29, 2021

Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

The first company to start human clinical trials of its coronavirus vaccine candidate in the United States — Moderna MRNA — has informed that it is on schedule to initiate the final-stage clinical trial by July. The last stage that will be arranged in partnership with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) would involve 30,000 participants in the United States and use a 100-microgram dose of the vaccine.

The company also informed that the trial’s primary aim is to prevent the spread of coronavirus. The trial’s secondary goals will involve the prevention of severe cases of the disease that might result in hospitalization for management and prevention of infection by SARS-CoV-2 — the virus responsible for causing COVID-19. Buoyed by the news, Moderna’s stock rose 0.2% on Jun 11 when the S&P 500 lost 5.9% on rising worries over the resurgence of coronavirus infections in the United States.

Leave a Reply

Your email address will not be published. Required fields are marked *